Participated · Seed · Jun 2025

Obviant ingests and unifies thousands of sources—such as program documents, defense budget justification books, and Congressional reports—to deliver a coherent picture of DoD acquisition, contracting, and budgeting information. The platform combines open-source intelligence (OSINT) with customers’ own data and uses AI-driven context and reasoning to surface opportunities and trends. Data can be aggregated by missions or programs (for example contested logistics or Golden Dome) to highlight actionable opportunities across the defense procurement ecosystem. Customers include high-growth defense startups, primes, global investment firms, defense advisory firms, think tanks, and multiple government agencies navigating the $1 trillion+ U.S. defense market. Obviant’s tools aim to help companies and the DoD align capabilities with sources of funding, provide diligence-ready analysis and market sizing, visualize portfolios, and streamline technology transitions. After its recent funding, the company plans to expand its team, advance the AI capabilities of its platform, and broaden its customer base.

Participated · Series A · Jan 2023

Angle Health provides an AI-powered, vertically integrated platform that combines underwriting, claims administration, and member engagement to streamline employer-sponsored health benefits. Its benefit-builder and quote-to-card tools let brokers generate firm underwritten quotes in minutes using only a census and activate groups in real time. The platform connects employers and employees to tailored healthcare plans, aiming to make benefits administration faster and more transparent. Led by CEO Ty Wang, the company plans to use new capital to expand operations and accelerate product development. Angle Health positions itself as a solution for businesses of any size seeking custom benefits packages and a consumer-grade healthcare experience. With the latest financing, the company’s total funding approaches $200 million, underscoring strong investor confidence in its growth trajectory.

Participated · Series B · Jan 2023

Vannevar Labs develops technology to address national security problems, best known for Decrypt, a text-workflow platform for government decision-making. Decrypt helps public servants understand, target, and respond to foreign actors and has been deployed across 15 major government agencies. Decrypt launched in January 2021 and has reached $25M in sales. The company launched two additional products in new mission areas in late 2022. Vannevar plans to use its new funding to develop new products and to win its first multi-year program for Decrypt. The company is led by CEO Brett Granberg and is based in Palo Alto, California. Vannevar Labs develops Vannevar Decrypt, a foreign-language natural language processing product that organizes, translates, and interprets overseas data for intelligence and foreign-policy decisionmakers. Decrypt officially launched in January and has expanded from one deployment to roughly a dozen adoptions within the intelligence community. The company emphasizes deep end-user engagement with DoD and intelligence customers to build mission-specific capabilities rather than pursuing dual-use commercial products. Vannevar has grown its team to about 20 employees, evenly split between national security experts and technologists, and says the team is set to double this year. Recent hires include Scott Sanders to lead business development and John Doyle joining the board; Brett Granberg is CEO and co-founder. The firm aims to broaden its product lines over time and to turn Decrypt into a program of record to secure sustained government sales. Vannevar is developing a platform that packages AI, machine learning, and natural language processing into services purchasable by defense and intelligence agencies. Its first product is focused on bringing NLP technologies like feature detection to international counterterrorism missions. Co‑founders Brett Granberg and Nini Moorhead draw on experience at In-Q-Tel, Lilt, and seven years of counterterrorism work to translate cutting‑edge techniques into government use cases. The company says it will apply proven techniques rather than invent new math, adapting existing approaches for specific government problems. Vannevar intends to work with agencies to embed ethics and policy guardrails to prevent misuse. Financially, the startup raised a $4.5 million seed round to support early product development and engagement with government procurement channels.

Participated · Equity · Dec 2021

Cooler Heads develops Amma™, which the company describes as the only FDA‑cleared portable scalp cooling system, designed to help chemotherapy patients keep their hair and preserve privacy. Amma provides infusion centers and patients flexibility to scalp cool where it is most convenient, using a continuous cooling system that eliminates the need for dry ice or frequent cap changes. By cooling the scalp before, during, and after chemotherapy, Amma reduces blood flow to hair follicles to shield them from chemotherapy drugs and prevent hair loss. The company was founded by breast cancer survivor Kate Dilligan, who serves as CEO. Cooler Heads positions Amma as a low‑friction therapy for infusion centers and notes the American Medical Association’s decision to elevate scalp cooling reimbursement codes to Category I starting January 2026 as creating momentum. The business also offers evidence‑based products, content, and services to help patients manage treatment side effects. Cooler Heads develops Amma, an FDA-cleared scalp-cooling medical device intended to help cancer patients undergoing chemotherapy preserve their hair. The company positions its product as dramatically less expensive and easier to use than existing scalp-cooling solutions. Founder and CEO Kate Dilligan, a cancer survivor, built an early prototype herself and pursued clinical relationships before raising institutional capital. Cooler Heads announced FDA clearance and said it has signed multiple commercial partnerships and will begin serving patients in Q1 2022. The company highlighted its mission-driven focus on patient dignity and plans to push commercialization to make scalp cooling broadly accessible. Cooler Heads has been backed by several venture investors and industry leaders and has participated in accelerators and medtech competitions.

Participated · Series B · Sep 2020

Siren develops Siren Socks, sensor-embedded socks that continuously measure foot temperature and detect hotspots to identify early signs of diabetic foot ulcers in real time. The company says continuous data collection can reduce DFU risk by up to 68% and amputations by 83%. Siren intends to use new funding to further develop the product and drive clinical adoption. Founder Ran Ma built early prototypes and the startup won TechCrunch’s Hardware Battlefield contest in 2017. Financially, Siren secured $9.5M in the latest strategic round (including an $8M check from Mölnlycke Health Care) and has now raised $43M to date. Past financing includes an $11.8M Series B with backers such as Khosla Ventures. Siren has developed proprietary technology to embed microsensors into fabric, enabling mass production of washable smart textiles. Its first commercial product is an FDA-registered temperature-monitoring sock for early detection of inflammation that can lead to diabetic foot ulcers. The products integrate into users’ everyday lives and provide real-time biofeedback to patients and their doctors. Diabetic foot ulcers cost the U.S. health system over $43 billion annually and lead to more than 100,000 lower-limb amputations, highlighting the market need. To support accelerated product demand, Siren is growing its team and is actively hiring, adding several engineering, sales, and executive hires over the past 12 months. Financially, Siren raised an additional $9M in Series B financing, bringing the total Series B to nearly $21M. Siren develops technology to embed microsensors within fabric to enable mass production of washable smart textiles for remote patient monitoring applications. Its first commercial product is an FDA-registered temperature-monitoring sock that connects wirelessly to a software application. The sock is designed to allow podiatrists to detect early signs of inflammation in patients at risk of developing diabetic foot ulcers. The company has focused on bringing the product to market and positioning itself for commercial expansion. Siren was founded in 2015 and is headquartered in San Francisco, CA. To date it has raised capital across multiple funding rounds to support commercialization. Siren has developed socks built with its Neurofabric technology that embed microsensors to monitor foot temperatures and surface-level changes for people with diabetes. Each sock contains six sensors (12 per pair), is machine-washable and requires no charging. The product is sold via a subscription priced at $19.95 per month, which includes an initial five-pair pack, replacement socks every six months, and access to the Siren Hub for monitoring. The company has iterated several versions of the socks and won TechCrunch’s Hardware Battlefield at CES. Siren plans to create additional health products using the same embedded-sensor approach and says the fabrication process is easily scalable. The company announced a $3.4 million investment from DCM, Khosla Ventures and Founders Fund.